Unibar’s CapsiClear receives European patent

In a recent press release, Unibar Corporation announced that their eye health ingredient, CapsiClear, has received a new European patent. The new ingredient is produced from Capsicum annum extract and is a carotenoid standardized to 50% capsanthin and may be able to bring ocular pressure into a normal range, support tear production as well as eye hydration, which may help individuals suffering from dry eye. CapsiClear received its patent on July 2, 2025.

The new patent is intended “for use in the reduction of intraocular pressure associated with normal tension glaucoma, primary open angle glaucoma, angle closure glaucoma, and/or combinations thereof.” Additionally, it will be provided for the United Kingdom, Italy, France, Switzerland, Poland, Ireland, Greece, Germany, Spain, and Hungary. With CapsiClear receiving the European patent, Unibar Corporation will be able to launch the ingredient into international markets.

“We are thrilled to receive this European patent for CapsiClear which underscores our long-standing commitment to best-in-class eye health research," said Sevanti, Mehta, president of Unibar, in a press release. "This decision validates the innovation behind Unibar’s portfolio and our continued efforts to deliver effective, natural solutions for eye wellness backed by both modern science and ancient tradition.”

Doug Lynch, CEO of MarketWell Nutrition Inc., commercial representative for Unibar Corporation, said, “We are very excited to help bring Unibar’s unparalleled botanical science to leading consumer health brands worldwide. Patented, market-ready CapsiClear will bring true product differentiation to all our brand partners.”

With receipt of the new patent, Unibar Corporation is working on targeted market campaigns to introduce CapsiClear to global partners, formulators, and health professionals to launch products ahead of major industry conferences in the fall of 2025.